Risedronate inhibits bone marrow mesenchymal stem cell adipogenesis and switches RANKL/OPG ratio to impair osteoclast differentiation

• Published in: The Journal of surgical research Vol. 180; no. 1; pp. e21 - e29
• Main Authors: Jin, Jian, Wang, Liang, Wang, Xiao-kai, Lai, Ping-lin, Huang, Min-jun, Jin, Da-di, Zhong, Zhao-ming, Chen, Jian-ting, Bai, Xiao-chun
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2013
• Subjects: Adipogenesis; Adipogenesis - drug effects; Bone Density Conservation Agents - pharmacology; Bone Marrow Cells - cytology; Bone Marrow Cells - drug effects; Bone marrow fat; Cell Differentiation - drug effects; Cells, Cultured; Dose-Response Relationship, Drug; Etidronic Acid - analogs & derivatives; Etidronic Acid - pharmacology; Humans; Mechanistic Target of Rapamycin Complex 1; Mesenchymal Stromal Cells - cytology; Mesenchymal Stromal Cells - drug effects; Multiprotein Complexes - antagonists & inhibitors; Osteoclast; Osteoclasts - cytology; Osteoclasts - drug effects; Osteoprotegerin; Osteoprotegerin - analysis; RANK Ligand - analysis; Receptor activator of nuclear factor-κB ligand; Risedronate; Risedronate Sodium; Surgery; TOR Serine-Threonine Kinases - antagonists & inhibitors; Risedronate; Bone marrow fat; Osteoclast; Receptor activator of nuclear factor-κB ligand; Adipogenesis; Osteoprotegerin

Osteoporosis is accompanied by an increase in bone marrow adipose tissue. Bone marrow adipogenesis has emerged as a therapeutic target for prevention of bone loss. Amino-bisphosphonates have been widely used for treatment of osteoporosis, but the mechanism through which amino-bisphosphonates inhibit...